HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fengxia Lv Selected Research

fengycin

8/2014Effects of fengycin from Bacillus subtilis fmbJ on apoptosis and necrosis in Rhizopus stolonifer.
7/2013Fengycin inhibits the growth of the human lung cancer cell line 95D through reactive oxygen species production and mitochondria-dependent apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Fengxia Lv Research Topics

Disease

2Infections
05/2021 - 03/2018
1Inflammation (Inflammations)
10/2021
1Atrophy
09/2021
1Ulcerative Colitis
09/2021
1Stomach Neoplasms (Stomach Cancer)
01/2019
1Blister (Bulla)
01/2017
1Coma (Comas)
03/2015
1Necrosis
08/2014
1Lung Neoplasms (Lung Cancer)
07/2013
1Neoplasms (Cancer)
07/2013

Drug/Important Bio-Agent (IBA)

2Proteins (Proteins, Gene)FDA Link
10/2021 - 03/2018
2bacillomycin DIBA
01/2019 - 03/2015
2fengycinIBA
08/2014 - 07/2013
1Oleic Acid (Oleate)IBA
10/2021
1Endoplasmic Reticulum Chaperone BiPIBA
10/2021
1Peroxidase (Myeloperoxidase)IBA
09/2021
1GlucansIBA
09/2021
1Dextran SulfateIBA
09/2021
1Fatty Acids (Saturated Fatty Acids)IBA
01/2019
1Interleukin-8 (Interleukin 8)IBA
03/2018
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
03/2018
1Peptides (Polypeptides)IBA
03/2018
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2018
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2018
1CytokinesIBA
03/2018
1Interleukin-6 (Interleukin 6)IBA
03/2018
1InulinFDA Link
03/2015
1Messenger RNA (mRNA)IBA
03/2015
1Ligases (Synthetase)IBA
03/2015
1Reactive Oxygen Species (Oxygen Radicals)IBA
07/2013

Therapy/Procedure

2Aftercare (After-Treatment)
05/2021 - 01/2017